Some Aspects of Dihydropyridine Calcium Antagonists in the Treatment of Hypertension Part 1

A.D. Radchenko

Abstract


This article is the first part of the review of the literature on the use of calcium antagonists in the treatment of hypertension. The questions about the history, classification, mechanisms of action, efficacy of lowering blood pressure and adverse reactions were considered. It is concluded that the dihydropyridine calcium antagonists do not differ from other classes of antihypertensive preparations by efficacy and safety, and in some situations they have advantages.


Keywords


hypertension; complications; calcium antagonists; safety

References


Алексеев В.В. Оптическая изомерия и фармакологическая активность лекарственных препаратов // Соросовский образовательный журнал «Химия». — 1998. — № 1. — С. 49-55.

Арсеньева К.Е. Применение амлодипина в кардиологической практике // РМЖ. — 2009. — № 17(8). — С. 610-613.

Воронков Л.Г. Клиническое использование хиральных молекул как новое направление в кардиоваскулярной медицине // Здоров’я України. — 2007. — № 21/1 (додатковий). — С. 31-32.

Галанова А.С., Осия А.О., Шилов А.М. Патофизиологические аспекты блокаторов кальциевых каналов в лечении сердечно-сосудистых заболеваний // РМЖ. — 2007. — № 20. — С. 1494-1497.

Дядык А.И., Багрий А.Э., Щукина Е.В. и др. Применение S-амлодипина в лечении больных артериальной гипертензией и ишемической болезнью сердца // Здоров’я України. — 2008. — № 23–24. — С. 54-55.

Кобалава Ж.Д., Терещенко С.Н., Калинкин А.Л. Суточное мониторирование артериального давления: методические аспекты и клиническое значение. — М., 1997. — 32 с.

Максимова М.А., Лукина Ю.В., Толпыгина С.Н. и др. Сравнительное изучение эффективности и безопасности нового препарата амлодипина — S-амлодипина у больных артериальной гипертонией I–II степени // Рациональная фармакотерапия в кардиологии. — 2008. — № 2. — С. 34-37.

Несукай Е.Г. «Левовращающий переворот» в кардиологии? // Артериальная гипертензия. — 2011. — № 1. — С. 14-18.

Acanfora D., Trojano L., Gheorghiade M. et al. A randomized, double-blind comparision of 10 and 20 mg lercanidipine in patients with stable ef ort angina: ef ects on myocardial ischemia and heart rate variability // Am. J. Ther. — 2002. — Vol. 9(5). — P. 444-453.

Alderman М., Cohen H., Roqué R. et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients // Lancet. — 1997. — Vol. 349. — P. 594-598.

Almas A., Rehman Iqbal S., Ehtamam A., Khan A. Spectrum of antihypertensive therapy in South Asians at a tertiary care hospital in Pakistan // BMC Research Notes. — 2011. — 4. — 318. doi:10.1186/1756-0500-4-318

Bang L., Chapman T., Goa K. Lercanidipine — a review of its ei cacy in management of hypertension // Drugs. — 2003. — Vol. 22. — P. 2449-2472.

Barrios V., Navarro A., Esteras A. et al. Investigators of ELYPSE Study (Ei cacia de Lercanidipino y su Peri l de Seguridad). Antihypertensive ei cacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Ei cacia de Lercanidipino y su Peri l de Seguridad // Blood Press. — 2002. — Vol. 11(2). — P. 95-100.

Birkett D.J. Racemates or enantiomers: regulatory approaches // Clin. Exp. Pharmacol. Physiol. — 1989. — Vol. 16(6). — P. 479-483.

Bjorklund K., Lind L., Zethelius B., Berglund L., Lithell H. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men // J. Hypertens. — 2004. — Vol. 22. — P. 1691-1697.

Borghi C., Prandin M.G., Dormi A., Ambrosioni E. Study Group of the Regional Unit of the Italian Society of Hypertension. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial // Blood Press Suppl. — 2003. — Suppl. 1. — P. 14-21.

Burges R.A., Gardiner D.G., Gwilt M. et al Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors // J. Cardiovasc. Pharmacol. — 1987. — Vol. 9. — P. 110-9.

Cai ero M., Giasi M. Long-term (12-month) treatment with lercanidipine in patients with mild to moderate hypertension // J. Cardiovasc. Pharmacol. — 1997. — Vol. 29, Suppl 2. — P. 45-49 S.

Chalmers J. All hats off to ALLHAT: a massive study with clear messages // J. Hypertension. — 2003. — Vol. 21. — P. 225-228.

Chen N., Zhou M., Yang M., Guo J. et al. Calcium channel blockers versus other classes of drugs for hypertension (Review) // Reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library. — 2010. — Issue 8. http://www.thecochranelibrary.com

Cohn J.N., Ziesche S., Smith R. et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-Heft III // Circulation. — 1997. — Vol. 96. — P. 856-863.

Costanzo P., Perrone-Filardi P., Petretta M. et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175 634 patients // J. Hypertens. — 2009. — Vol. 27. — P. 1136-1151.

Cuffe R.L., Rothwell P.M. Medium-term variability in systolic blood pressure is an independent predictor of stroke // Cerebrovasc. Dis. — 2005. — Vol. 19, suppl. 2. — P. 51.

Dahlöf B., Sever P.S., Poulter N.R. et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366. — P. 895-906.

Deroubaix X., Lins R.L., Lens S. et al. Single dose pharmacokinetics of manidipine in hepatic impaired patients and healthy controls // Int. J. Clin. Pharmacol. Ther. — 1998. — Vol. 36. — P. 386-391.

Epstein M. Calcium Antagonists in Clinical Medicine. — HANLEY&BELFUS: Philadelphia, 2002. — 852 p.

Escargueil-Blanc I., Meilhac O., Pieraggi M.T. et al. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aurintricarboxylic acid // Arterioscler. Thromb. Vasc. Biol. — 1997. — Vol. 17. — P. 331-339.

Fleckenstein A. History of calcium antagonists // Circ. Res. — 1983. — Vol. 52, Pt 2. — P. 13-16.

Furberg C., Psaty B., Meyer J. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease // Circulation. — 1995. — Vol. 92. — P. 1326-1331.

Galli C., Meucci O., Scorziello A. et al. Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis // J. Neurosci. — 1995. — Vol. 15. — P. 1172-1179.

Gillman M.W., Ross-Degnan D., McLaughlin T.J. et al. Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction // J. Am. Geriatr. Soc. — 1999. — Vol. 47. — P. 512-517.

Girerd X. et al. / Analysis of the use of antihypertensive drugs in five European countries in 2010 / ESH London 29th April.

Gong L., Zhang W., Zhu Y. et al. Shanghai trial of nifedipine in the elderly (STONE) // J. Hypertens. — 1996. — Vol. 14(10). — P. 1237-45.

Gu Q., Burt V., Dillon C., Yoon S. Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension The National Health and Nutrition Examination Survey, 2001 to 2010 // Circulation. — 2012. — Vol. 126. — P. 2105-2114.

Halici Z., Borekci B., Ozdemir Y., Cadirci E., Suleyman H. Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats // Eur. J. Pharmacol. — 2008. — Vol. 579(1–3). — P. 241-245.

Hansson L., Lindholm L.H., Ekbom T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. — 1999. — Vol. 354. — P. 1751-1756.

Hansson L., Zanchetti A., Carruthers S.G., et al. The HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial // Lancet. — 1998. — Vol. 351. — P. 1755-1762.

Isles C., Walker L., Beevers G. et al. Mortality in patients of the Glasgow blood pressure clinic // J. Hypertens. — 1986. — Vol. 4. — P. 141-156.

Jick H., Jick S., Derby L.E., Vasilakis C. et al. Calcium channel blockers and risk of cancer // Lancet. — 1997. — Vol. 349. — P. 525-528.

Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363. — P. 2022-2031.

Kaplan N. The meaning of ALLHAT // Journal of Hypertension. — 2003. — 21(2). — 233-234.

Kario. Early morning risk management in hypertension. — Science press: London, 2004. — 68 p.

Kikuya M., Hozava A., Ohokubo T. et al. Prognostic Significance of Blood Pressure and Heart Rate Variabilities // Hypertension. — 2000. — Vol. 36. — P. 901-906.

Koike T., Martin D.P., Johnson E.M. Jr. Role of Ca21 channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor deprivation: evidence that levels of internal Ca21 determine nerve growth factor dependence of sympathetic ganglion cells // Proc. Natl. Acad. Sci. USA. — 1989. — Vol. 86. — P. 6421-6425.

Kondo S., Yin D., Morimura T., Takeuchi J. Combination therapy with cisplatin and nifedipine inducing apoptosis in multidrug-resistant human glioblastoma cells // J. Neurosurg. — 1995. — Vol. 82. — P. 469-474.

Leszczynski D., Zhao Y., Luokkamaki M., Foegh M.L. Apoptosis of vascular smooth muscle cells: protein kinase C and oncoprotein Bcl-2 are involved in regulation of apoptosis in non-transformed rat vascular smooth muscle cells // Am. J. Pathol. — 1994. — Vol. 145. — P. 1265-70.

Liu L., Zhang Y., Liu G. et al. The Felodipine EVEnt Reduction (FEVER) study: A randomized long–term placebo controlled trial in Chinese hypertensive patients — design and principal results // J. Hypertens. — 2005. — Vol. 23, Suppl. 2. —

P. 118S. Abstract P1.347.

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. — 2002. — Vol. 288. — Р. 2981-2997.

Malacco E., Mancia G., Rappelli A. et al. Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results // Blood press. — 2003. — Vol. 12. — P. 160-167.

Mancia G., Brown M., Castaigne A. et al. INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT) // Hypertension. — 2003. — Vol. 41. — P. 431-436.

Mancia G., Bombelli, R. Facchetti et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study // Hypertension. — 2007. — Vol. 49. — P. 1265-1270.

Mason P. Calcium Channel Blockers, Apoptosis and Cancer: Is There a Biologic Relationship? // Journal of the American College of Cardiology. — 1999. — Vol. 34. — P. 1857-1866.

Mason R.P. Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action (abstr) // Am. J. Hypertens. — 1998. — Vol. 11. — P. 245A.

Morgan T., Lauri J., Bertram D. et al. Effect of different antihypertensive drug classes on central aortic pressure // Am. J. Hypertens. — 2004. — Vol. 17. — P. 118-123.

Muntner P., Shimbo D., Tonelli M. et al. The relationship between visit to visit variability in systolic blood pressure and all cause mortality in the general population: finding from NHANES III 1988 to 1994 // Hypertension. — 2011. — Vol. 57. — P. 160-166.

Nayler W.G. Amlodipine. Springer, Berlin-Heidelberg-New York, 1993. Borchard U. Calcium antagonists in comparison: view of the pharmacologist // J. Cardiovasc. Pharmacol. — 1994. — Vol. 24. — Suppl 2. — P. 85-91.

Ohmori M., Arakawa M., Harada K. et al. Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients // Am. J. Ther. — 2203. — Vol. 10(1). — P. 29-31.

Olsen J.H., Sorensen H.T., Friis S., McLaughlin J.K., Steffensen F.H., Nielsen G.L. Cancer risk in users of calcium channel blockers // Hypertension. — 1997. — Vol. 29. — P. 1091-1094.

Ortiz M., Calcino G. Inferred mortality differences be-tween dihydropiridine antihypertensives // Hypertension. — 2009. — Vol. 53. — P. 1116.

Packer M., O’Connor M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure // N. Engl. J. Med. — 1996. — Vol. 335. — P. 1107-1114.

Pahor M., Guralnik J.M., Ferrucci L., Corti M.-C., Salive M.E., Cerhan J.R. et al. Calcium-channel blockade and incidence of cancer in aged populations // Lancet. — 1996. — Vol. 348. — P. 493-497.

Pahor M., Guralnik J.M., Salive M.E., Corti M.-C., Carbonin P., Havlik R.J. Do calcium channel blockers increase the risk of cancer? // Am. J. Hypertens. — 1996. — Vol. 9. — P. 695-699.

Pahor M., Guralnik J., Corti M. et al. Long-term survival and use of antihypertensive medications in older persons // J. Am. Ger. Soc. — 1995. — Vol. 43. — P. 1-7.

Patil P.A., Kothekar M.A. Development of safer molecules through chirality // Indian. J. Med. Sci. — 2006. — Vol. 60. — P. 427-437.

Paudel R., Palaian S., Kishore P.V. et al. Peripheral oedema due to S-amlodipine — a report of three cases // J. Clin. Diagn. Res. — 2007. — Vol. 6. — P. 533-516.

Poole-Wilson P.A., Lubsen J., Kirwan B.A. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial // Lancet. — 2004. — Vol. 364. —

P. 849-857.

Psat В., Heckbert S., Koepsell T. et al. The risk of myocardial infarction associated with antihypertensive treatment // JAMA. — 1995. — Vol. 274. — P.620-625.

Rothwell P. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension // The Lancet. — 2010. — Vol. 375. — P. 938-948.

Rothwell P.M., Howard S.C., Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension // Lancet. — 2010. — Vol. 375. — P. 895-905.

Rothwell P.M., Howard S.C., Dolan E. et alon behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke // Lancet Neurol. — 2010. — Vol. 9. — P. 469-480.

Sakurai-Yamashita Y., Harada N. and Niwa M. Lercanidipine Rescues Hippocampus Pyramidal Neurons from Mild Ischemia-Induced Delayed Neuronal Death in SHRSP // Cell. Mol. Neurobiol. — 2011 Jan 23. — Р. 1-7. doi:10.1007/s10571-011-9649-6

Sander D., Kukla C., Klingelhofer J. et al. Relationship between circadian blood pressure patterns and progression of earlycarotid atherosclerosis // Circulation. — 2000. — Vol. 102. — P. 1536-1541.

SESA study group — Safety and efficacy of S(–) Amlodipi­ne // JAMA India. — 2003. — Vol. 2(8). — P. 87-92.

SESA II study group, India. Safety and efficacy of S(–) amlodipine in the treatment of hypertension // Indian. Med. Gae. — 2005. — Vol. 529. — P. 33.

SMD data base, упак. Квітень 2012.

Smilde J. Comparison of amlodipine and felodipine extend release in treatment of hypertension at steady state and after two missed doses // Curr. Ther. Res. — 1997. — Vol. 58. — P. 141-153.

Staessen J., Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic Hypertension // Lancet. — 1997. — Vol. 350. — P. 757-764.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs DiureticThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA. — 2002. — Vol. 288(23). — P. 2981-2997-3399.

Toyo-Oka T., Nayler W. Third generation calcium entry blockers // Blood Press. — 1996. — Vol. 5(4). — P. 206-208.

Wang J.G., Staessen J.A., Gong L., Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group // Arch. Intern. Med. — 2000. — Vol. 160(2). — P. 211-20.

Webb A.J., Fischer U., Mehta Z., Rothwell P.M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis // Lancet. — 2010. — Vol. 375. — P. 906-15.

White W. Blood pressure monitoring in cardiovascular medicine and therapeutics. — New Jersey: Humana Press, 2001. — 308 p.

Zanchetti A., Bond M., Hennig M. et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial // Circulation. — 2002. — Vol. 106. — P. 2422-2427.

Zhang X.P., Loke K.E., Mital S. et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine // J. Cardiovasc. Pharmacol. — 2002. — Vol. 39(2). — P. 208-214.




DOI: https://doi.org/10.22141/2224-1485.5.31.2013.86473

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru